Adenosine (Ado) kinase (ADK; ATP:Ado 5Ј phosphotransferase, EC 2.7.1.20) catalyzes the salvage synthesis of adenine monophosphate from Ado and ATP. In Arabidopsis, ADK is encoded by two cDNAs that share 89% nucleotide identity and are constitutively, yet differentially, expressed in leaves, stems, roots, and flowers. To investigate the role of ADK in plant metabolism, lines deficient in this enzyme activity have been created by sense and antisense expression of the ADK1 cDNA. The levels of ADK activity in these lines range from 7% to 70% of the activity found in wild-type Arabidopsis. Transgenic plants with 50% or more of the wild-type activity have a normal morphology. In contrast, plants with less than 10% ADK activity are small with rounded, wavy leaves and a compact, bushy appearance. Because of the lack of elongation of the primary shoot, the siliques extend in a cluster from the rosette. Fertility is decreased because the stamen filaments do not elongate normally; hypocotyl and root elongation are reduced also. The hydrolysis of S-adenosyl-l-homo-cysteine (SAH) produced from S-adenosyl-l-methionine (SAM)-dependent methylation reactions is a key source of Ado in plants. The lack of Ado salvage in the ADK-deficient lines leads to an increase in the SAH level and results in the inhibition of SAMdependent transmethylation. There is a direct correlation between ADK activity and the level of methylesterified pectin in seed mucilage, as monitored by staining with ruthenium red, immunofluorescence labeling, or direct assay. These results indicate that Ado must be steadily removed by ADK to prevent feedback inhibition of SAH hydrolase and maintain SAM utilization and recycling.

Ultrasound stimulated microbubbles (USMB) are being investigated for their potential to promote the uptake of anticancer agents into tumor tissue by exploiting their ability to enhance microvascular permeability. At sufficiently high ultrasound transmit amplitudes it has also recently been shown that USMB treatments can, on their own, induce vascular damage, shutdown blood flow, and inhibit tumor growth. The objective of this study is to examine the antitumor effects of ‘antivascular’ USMB treatments in conjunction with chemotherapy, which differs from previous work which has sought to enhance drug uptake with USMBs by increasing vascular permeability. Conceptually this is a strategy similar to combining vascular disrupting agents with a chemotherapy, and we have selected the taxane docetaxel (Taxotere) for evaluating this approach as it has previously been shown to have potent antitumor effects when combined with small molecule vascular disrupting agents. Experiments were conducted on PC3 tumors implanted in athymic mice. USMB treatments were performed at a frequency of 1 MHz employing sequences of 50 ms bursts (0.00024 duty cycle) at 1.65 MPa. USMB treatments were administered on a weekly basis for 4 weeks with docetaxel (DTX) being given intravenously at a dose level of 5 mg/kg. The USMB treatments, either alone or in combination with DTX, induced an acute reduction in tumor perfusion which was accompanied at the 24 hour point by significantly enhanced necrosis and apoptosis. Longitudinal experiments showed a modest prolongation in survival but no significant growth inhibition occurred in DTX–only and USMB-only treatment groups relative to control tumors. The combined USMB-DTX treatment group produced tumor shrinkage in weeks 4–6, and significant growth inhibition and survival prolongation relative to the control (p<0.001), USMB-only (p<0.01) and DTX-only treatment groups (p<0.01). These results suggest the potential of enhancing the antitumor activity of docetaxel by combining it with antivascular USMB effects.

Considerable effort is being directed toward investigating the use of ultrasound (US) stimulated microbubbles (MB) to promote the uptake of anticancer agents in tumors. In this study we propose and investigate a new method for combining therapeutic ultrasound with anticancer agents, which is to induce antivascular effects and combine these with an antiangiogenic treatment strategy, in this case metronomic chemotherapy. This is effectively a vascular targeting rather than a drug delivery approach. Experiments were conducted on MDA-MB-231 breast cancer tumors implanted in athymic mice. Metronomic cyclophosphamide (MCTX) was employed as an antiangiogenic therapy and was administered through the drinking water. Ultrasound stimulated microbubble treatments (USMB) were conducted at 1 MHz employing short bursts (0.00024 duty cycle) at 1.6 MPa in combination with the commercial microbubble agent Definity. USMB treatments were performed on a weekly basis for 4 weeks and MCTX was administered for 10 weeks. The USMB induced an acute reduction of blood flow as confirmed with US contrast imaging and DiOC 7 perfusion staining. Longitudinal experiments demonstrated that significant growth inhibition occurred in MCTX-only and USMB-only treatment groups relative to control tumors. The combined USMB and MCTX treatment group showed significant growth inhibition and survival prolongation relative to the USMB-only (p < 0.01) and MCTX-only treatment groups (p < 0.01). These results indicate the feasibility of a new approach to combining therapeutic ultrasound with an anticancer agent.Therapeutic ultrasound (US) is emerging as a nonsurgical approach for the treatment of a range of solid tumor types. 1The method employed in clinical work at present is to ablate tumor tissue with high intensity focused ultrasound (HIFU), which exploits the absorption of US energy by tissue. It is also under investigation as a means by which to promote the delivery of anticancer agents to tumor tissue.2 Hyperthermia is one method for accomplishing this, whereby mild temperature elevations induced by US promote the local release and uptake of therapeutic agents. Another approach for US-mediated drug delivery is to use US to induce oscillations of microbubbles (MBs), which are systemically injected encapsulated bubbles currently in clinical use as diagnostic contrast agents.3 This is based on substantial research demonstrating that microvascular permeability can be increased by oscillating MBs. 4,5 These effects have been shown in a range of tissue types, 2,6 though relevant work in tumors has been limited and, outside the brain, clear evidence of enhanced therapeutic effects of anticancer agents with US stimulated MBs remains to be established. [7][8][9] In addition to microvessel permeabilization effects, which generally occur at relatively low US amplitudes, the stimulation of circulating MBs with sufficiently high US amplitudes can cause microvascular damage. [10][11][12] While the precise mechanisms of damage are not well understood at present, there ...

Gene expression programs are established by networks of interacting transcription factors. The basic helix-loop-helix factor SCL and the LIM-only protein LMO2 are components of transcription factor complexes that are essential for hematopoiesis. Here we show that LMO2 and SCL are predominant interaction partners in hematopoietic cells and that this interaction occurs through a conserved interface residing in the loop and helix 2 of SCL. This interaction nucleates the assembly of SCL complexes on DNA and is required for target gene induction and for the stimulation of erythroid and megakaryocytic differentiation. We also demonstrate that SCL determines LMO2 protein levels in hematopoietic cells and reveal that interaction with SCL prevents LMO2 degradation by the proteasome. We propose that the SCL-LMO2 interaction couples protein stabilization with higher order protein complex assembly, thus providing a powerful means of modulating the stoichiometry and spatiotemporal activity of SCL complexes. This interaction likely provides a rate-limiting step in the transcriptional control of hematopoiesis and leukemia, and similar mechanisms may operate to control the assembly of diverse protein modules.

A large number of compounds including lignin, phospholipids, pectin, DNA, mRNA, and proteins require methyl groups for their functionality. A detailed study of the expression and activities of two enzymes, adenosine kinase (ADK) and S-adenosylhomocysteine hydrolase (SAHH), which are both required for the maintenance and recycling of S-adenosylmethionine-dependent methylation in plants, was carried out. The abundance and tissue localization of ADK and SAHH transcripts and protein were monitored along with their enzyme activities in leaves, stems, buds, siliques, and roots of Arabidopsis. In all but roots and seed coats, the transcript abundance of ADK and SAHH fluctuated co-ordinately, matching changes in their protein and enzyme activities. To evaluate whether this expression pattern was associated with methyl recycling, the protein content and distribution of S-adenosylmethionine synthetase and phosphoethanolamine N-methyltransferase, a key methyltransferase involved in phospholipid synthesis, were investigated. These were found to accumulate in a pattern similar to ADK and SAHH. ADK and SAHH protein and transcript amounts were shown to fluctuate similarly in tissues accumulating lignin. Additionally, the amounts of ADK and SAHH mRNAs were also found at high levels in inflorescence meristems likely to support their higher rates of cell division. Thus, the results point to a co-ordinated and probably transcriptional regulation of these genes in most organs of Arabidopsis; SAHH abundance is distinctly higher in seeds and roots which suggests it may have a non-methyl-related role in these organs.

No abstract

To monitor the subcellular distribution of mixed epidermal growth factor (EGF) receptor (EGFR)-DNA targeting drugs termed combi-molecules, we designed AL237, a fluorescent prototype, to degrade into a green fluorescent DNA damaging species and FD105, a blue fluorescent EGFR inhibitor. Here we showed that AL237 damaged DNA in the 12.5 to 50 μmol/L range. Despite its size, it blocked EGFR phosphorylation in an enzyme assay (IC 50 = 0.27 μmol/L) and in MDA-MB468 breast cancer cells in the same concentration range as for DNA damage. This translated into inhibition of extracellular signal-regulated kinase 1/2 or BAD phosphorylation and downregulation of DNA repair proteins (XRCC1, ERCC1). Having shown that AL237 was a balanced EGFR-DNA targeting molecule, it was used as an imaging probe to show that (a) green and blue colors were primarily colocalized in the perinuclear and partially in the nucleus in EGFR-or ErbB2-expressing cells, (b) the blue fluorescence associated with FD105, but not the green, was colocalized with anti-EGFR redlabeled antibody, (c) the green fluorescence of nuclei was significantly more intense in NIH 3T3 cells expressing EGFR or ErbB2 than in their wild-type counterparts (P < 0.05). Similarly, the growth inhibitory potency of AL237 was selectively stronger in the transfectants. In summary, the results suggest that AL237 diffuses into the cells and localizes abundantly in the perinuclear region and partially in the nucleus where it degrades into EGFR and DNA targeting species. This bystander-like effect translates into high levels of DNA damage in the nucleus. Sufficient quinazoline levels are released in the cells to block EGF-induced activation of downstream signaling. Mol Cancer Ther; 9(4); 869-82. ©2010 AACR.

Mixed-ligand palladium(II) complexes of the type [(DT)Pd(PR 3 )Cl], where DT = diethyldithiocarbamate (1), dibutyldithiocarbamate (2,3), dipropyldithiocarbamate (4,5), bis(2-methoxyethyl)dithiocarbamate; PR 3 = benzyldiphenylphosphine (1,4), diphenyl-otolylphosphine (2), diphenyl-t-butylphosphine (3), P-chlorodiphenylphosphine (5) and triphenylphosphine (6), have been synthesized and characterized by elemental analyses and FT-IR, Raman and multinuclear NMR spectroscopy. The structures of compounds 1 and 2 were determined by single-crystal X-ray diffraction (XRD) measurements and these analyses showed that the complexes have pseudo square-planar geometry around the Pd(II) and that the dithiocarbamate ligand is bound in a bidentate fashion, while the remaining two positions are occupied by a tertiary organophosphine and a chloride ligand. The anticancer studies showed that the Pd(II) complexes are highly active against cisplatin-resistant DU145 human prostate carcinoma (HTB-81) cells with the highest activity shown by compound 6 (IC 50 = 2.12 mM). The redox behavior and ds-DNAdenaturing ability of the complexes were studied by cyclic voltammetry and two reduction and one oxidation waves were observed. The decrease in the reduction peak currents illustrated the consumption of the mixed-ligand drug by the DNA molecule.